DHT Mechanism

Conversion: Testosterone → 5αR enzyme → DHT.
Binding: DHT binds to androgen receptors in genetically sensitive follicles.
Miniaturization: Shortens growth phase → follicle shrinks → thinner hairs → eventual dormancy.
Pattern specificity: Affects temples, frontal hairline, crown. Donor area (back/sides) remains resistant.
Key distinction: Normal testosterone levels. Condition is follicle sensitivity, not hormone imbalance.

Enzymes & Genetics

There are 2 iso-forms of 5-Alpha Reductase: Type I & 2

Type I : 5-Alpha Reductase

Primary locations: Sebaceous glands, epidermis (skin), liver, brain, and adrenal glands.
Function: Involved in skin physiology, sebum production, and neurosteroid metabolism.
pH optimum: Functions optimally at pH 6.0–8.5 (neutral to alkaline).
Hair follicle role: Minor presence in the outer root sheath. Not the primary isoform in the dermal papilla.

Type II : 5-Alpha Reductase

Primary locations: Hair follicles (dermal papilla), prostate, seminal vesicles, epididymis, and liver (minor).
Function: Primary enzyme for DHT production in androgen-sensitive tissues including hair follicles and prostate.
pH optimum: Functions optimally at pH 5.0–6.0 (acidic).
Hair follicle role: Predominantly expressed in the dermal papilla and outer root sheath of scalp hair follicles.

Inheritance (Both Parents)

Maternal (X chromosome): Androgen receptor gene — explains correlation with maternal grandfather.
Paternal (autosomal): Other genes affecting follicle function, enzyme activity, inflammation.

Relevance to Pattern Hair Loss

Type II predominance: Research indicates that Type II 5-alpha-reductase is the primary isoform expressed in human scalp hair follicles, particularly in the dermal papilla cells.
Regional variation: Studies have shown that Type II enzyme activity may be higher in frontal and temporal scalp regions compared to occipital (donor) regions in individuals with pattern hair loss.
DHT production: Local DHT production within the hair follicle — via Type II enzymatic conversion — is considered more biologically relevant than circulating DHT levels.
Type I role: Type I may contribute to sebum production and skin health but is not considered the primary driver of hair follicle miniaturization.

Clinical observation: The differential distribution of Type II 5-alpha-reductase in susceptible scalp regions aligns with the patterned nature of androgenetic alopecia — affecting frontal, temporal, and crown areas while sparing the occipital donor zone.

Enzyme-Targeting in Clinical Research

The question of which enzyme isoform to target is informed by the tissue distribution and biological role of each type.

Type II Targeting

Rationale: Type II is the predominant isoform in hair follicles and the prostate.
Selectivity: Agents that selectively inhibit Type II reduce DHT production in hair follicles while potentially preserving Type I activity in skin and other tissues.
Clinical literature: Published studies have investigated Type II inhibition in the context of androgenetic alopecia and benign prostatic hyperplasia.

Type I Targeting

Rationale: Type I is present in skin, sebaceous glands, and brain. Its role in hair follicle miniaturization is less clearly established in current literature.
Considerations: Inhibition of Type I may affect sebum production and neurosteroid metabolism. The clinical significance of these effects continues to be studied.

Dual Targeting (Both Types)

Approach: Some research has examined agents that inhibit both Type I and Type II isoforms.
Trade-offs: Broader enzyme inhibition may result in more complete DHT reduction but also affects a wider range of tissues.
Current understanding: The relative importance of Type I versus Type II in hair loss continues to be investigated in clinical research.

Research context: Medical literature indicates that Type II 5-alpha-reductase is the primary isoform in human scalp hair follicles. The clinical significance of Type I inhibition for hair loss treatment remains an area of ongoing investigation.

"Natural" DHT Blockers (Saw Palmetto)

Limited efficacy: Weak inhibitory effect compared to Finasteride. Inconsistent results in trials.
Not risk-free: Any 5αR inhibition carries potential for similar side effects.
Lack of regulation: No purity, potency, or dosage consistency.
Medical consensus: Prescribed, dose-controlled Finasteride is more effective and reliable.

Frequently Asked Questions

Q: Does blocking DHT affect masculinity or muscle? No. Testosterone is primary for masculinity and muscle. Finasteride blocks DHT conversion but does not lower testosterone.

Q: Can women take DHT blockers? Finasteride is contraindicated for premenopausal women (birth defect risk). May be considered for postmenopausal women under strict supervision. Topical Minoxidil is first-line for female pattern hair loss.

Q: What happens if treatment stops? Effect is reversible. DHT rises, hair loss resumes. Maintained hair typically lost within 6–12 months.

Q: Are side effects permanent? For vast majority, side effects are reversible upon stopping. Persistent side effects are very rare in large-scale studies.

Q: Which enzyme type is more important for hair loss? Current research suggests Type II 5-alpha-reductase is the primary isoform in scalp hair follicles and plays a more direct role.

Q: Are there genetic differences in enzyme types? Yes. Genetic variations in the SRD5A2 gene (encoding Type II) have been studied in relation to pattern hair loss susceptibility.

Q: Does Type I affect hair at all? Type I is present in sebaceous glands and may influence scalp environment through sebum production, but its direct role in follicular miniaturization is less established.

Q: Why does donor hair resist DHT? Research indicates that occipital scalp follicles may have lower levels of Type II 5-alpha-reductase activity and androgen receptor expression compared to frontal follicles.

5 Alpha-Reductase & DHT: Science of Hair Loss